"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident"

-Arthur Schopenhauer

If you are one of the people short Opko Health (OPK) and stumbled upon the company's recent features in The New York Times, Bloomberg Markets Magazine and CNBC's Mad Money all in just this past month, it would make sense that you should be extremely concerned. The cause for concern is not merely the company's being featured in these major outlets, but the fact that the greater public is finally recognizing OPK as a revolutionary biotech stock that looks to be just getting started. Arthur Schopenhauer's quote listed above is all too typical of the career of Dr. Phillip Frost. When Dr. Frost brought forth his first company Key Pharmaceuticals in 1972, it became highly shorted. The company was losing money and people

In my previous article on Opko Health (OPK), I discussed several of the forefront products the company is working to bring to market in the near future. Since that article, to my surprise, Opko's CEO Dr. Phillip Frost was asked to be interviewed on Jim Cramer's Mad Money where he further discussed the future of his company. You can view this recent interview here. Disclosed by Dr. Frost was that one of the drugs acquired from Cytochroma which will be the soonest one to complete phase III trials, has a 12 billion dollar market potential in the U.S. and nearly the same size market potential in Japan. Dr. Frost states that the competition for Opko's newest drug currently consists of only two competitor drugs and that these drugs are inadequate in effectiveness.

In assessing the potential market value for Opko's newest phase III

With the current 3D printing market in a state of frenzy, many companies like 3D Systems Corporation (DDD), Stratasys (SSYS), Cimatron (CIMT) and Perceptron (PRCP) sit to reap potentially large benefits. In this article however I will take a look at what I feel to be the most unique 3D printing company, Organovo Holdings Inc. (ONVO) (ONVO.PK). Organovo is a company which creates functional living human tissue using a proprietary 3D biological printing technology. CEO Keith Murphy says that the company accomplishes this by placing living human cells into a 3D matrix that can then grow into human tissue. Manufacturing 3D biological tissue however is not the only venture in Organovo's business model.

The company also has a division which aims to work directly with pharmaceutical companies who are looking for more efficient ways to test new drugs. One of the major problems that pharmaceutical companies can face when

Spotting a new technology that has the potential to revolutionize an industry is a difficult task. In 1984 when Apple (AAPL) released its first Macintosh computer, most people did not take note or have the foresight to speculate where the company could take its novel technology in years to come. In 2011, however, when Claros Diagnostics introduced its first desktop diagnostics analyzer that delivers up to 20 disease diagnoses within minutes from a drop of blood, many seemed to take note. The company was profiled among Google (GOOG), IBM (IBM), Apple, Amazon (AMZN) and others as being one of the 50 most innovative companies in the world for 2011 by the MIT Technology Review. The general sentiment was that this company's product could potentially revolutionize the entire medical industry.

Another company working in the same area of next generation medical diagnostics happened to take note of this new technology platform